Risultati della ricerca - Daniel Rayson

Seronegative Paraneoplastic Opsoclonus–Myoclonus–Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin di Geraint Berger, Caitlin Jackson-Tarlton, Daniel Rayson, Alexander Silver, Mark Walsh, Ashley Drohan

Testo

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center di John Loggie, Penelope J. Barnes, Michael D. Carter, Daniel Rayson, Gillian C. Bethune

Testo

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective di Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah

Testo

Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review di Margaret Sheridan, Bruce Colwell, Nathan W. D. Lamond, Robyn Macfarlane, Daniel Rayson, Stephanie Snow, Lori A. Wood, Ravi Ramjeesingh

Testo

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain di Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

Testo

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Canc... di Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

Testo

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study di Daniel Rayson, Jonathan Bertin, Maxim Lemelin, Madeline Tong, Ryan Ng, Philip Ding, Winson Y. Cheung, Arushi Sharma, Phu Vinh On, Guillaume Feugère, Sasha Lupichuk

Testo